Clinical trial · no report yet · Phase 1/Phase 2
NCT04179162
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment
- NCT04179162 ↗
- Active, not recruiting
- Memorial Sloan Kettering Cancer Center
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase I/II Trial of Bacillus Calmette-Guérin (BCG) and Intravesical Gemcitabine for Patients With BCG-Relapsing High-Grade Non-Muscle Invasive Bladder Cancer
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Non-Muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- Bacillus Calmette-Guérin (BCG); Gemcitabine
- Arms
- Bacillus Calmette-Guérin (BCG) and Gemcitabine · Experimental
- Enrollment
- 54
- Primary outcomes
- evaluate the MTD (Phase I)
- proportion of patients who are disease free
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 22, 2019
- Primary completion
- Nov 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04179162 · updated Aug 11, 2026